1277 related articles for article (PubMed ID: 1370679)
21. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta.
Moretta A; Poggi A; Pende D; Tripodi G; Orengo AM; Pella N; Augugliaro R; Bottino C; Ciccone E; Moretta L
J Exp Med; 1991 Dec; 174(6):1393-8. PubMed ID: 1720808
[TBL] [Abstract][Full Text] [Related]
22. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
Ranheim EA; Kipps TJ
J Exp Med; 1993 Apr; 177(4):925-35. PubMed ID: 7681471
[TBL] [Abstract][Full Text] [Related]
23. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
Chen L; Ashe S; Brady WA; Hellström I; Hellström KE; Ledbetter JA; McGowan P; Linsley PS
Cell; 1992 Dec; 71(7):1093-102. PubMed ID: 1335364
[TBL] [Abstract][Full Text] [Related]
24. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
25. CD28- T lymphocytes. Antigenic and functional properties.
Azuma M; Phillips JH; Lanier LL
J Immunol; 1993 Feb; 150(4):1147-59. PubMed ID: 8381831
[TBL] [Abstract][Full Text] [Related]
26. Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation.
Hirokawa M; Gray JD; Takahashi T; Horwitz DA
J Immunol; 1992 Sep; 149(6):1859-66. PubMed ID: 1355500
[TBL] [Abstract][Full Text] [Related]
27. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.
de Waal Malefyt R; Yssel H; de Vries JE
J Immunol; 1993 Jun; 150(11):4754-65. PubMed ID: 7684412
[TBL] [Abstract][Full Text] [Related]
28. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
Bolhuis RL; Roozemond RC; van de Griend RJ
J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
[TBL] [Abstract][Full Text] [Related]
29. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.
Galea-Lauri J; Darling D; Gan SU; Krivochtchapov L; Kuiper M; Gäken J; Souberbielle B; Farzaneh F
J Immunol; 1999 Jul; 163(1):62-70. PubMed ID: 10384100
[TBL] [Abstract][Full Text] [Related]
30. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
Linsley PS; Clark EA; Ledbetter JA
Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5031-5. PubMed ID: 2164219
[TBL] [Abstract][Full Text] [Related]
31. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
32. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes.
Clements JL; Winslow G; Donahue C; Cooper SM; Allison JP; Budd RC
Int Immunol; 1993 Nov; 5(11):1451-60. PubMed ID: 7903158
[TBL] [Abstract][Full Text] [Related]
33. CD28 co-stimulation of T-cell-mediated cytotoxicity.
Azuma M; Phillips JH; Lanier LL
Int J Cancer Suppl; 1992; 7():33-5. PubMed ID: 1330948
[TBL] [Abstract][Full Text] [Related]
34. Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation.
Van de Wiel-van Kemenade E; Te Velde AA; De Boer AJ; Weening RS; Fischer A; Borst J; Melief CJ; Figdor CG
Eur J Immunol; 1992 Jun; 22(6):1467-75. PubMed ID: 1376259
[TBL] [Abstract][Full Text] [Related]
35. Accessory signalling by B7-1 for T cell activation induced by anti-CD2: evidence for IL-2-independent CTL generation and CsA-resistant cytokine production.
Van Gool SW; Kasran A; Wallays G; de Boer M; Ceuppens JL
Scand J Immunol; 1995 Jan; 41(1):23-30. PubMed ID: 7529939
[TBL] [Abstract][Full Text] [Related]
36. Activation of T lymphocytes via monoclonal antibodies against rat cell surface antigens with particular reference to CD2 antigen.
Beyers AD; Barclay AN; Law DA; He Q; Williams AF
Immunol Rev; 1989 Oct; 111():59-77. PubMed ID: 2576418
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD48 (murine CD2 ligand) mAbs suppress cell mediated immunity in vivo.
Chavin KD; Qin L; Lin J; Woodward J; Baliga P; Kato K; Yagita H; Bromberg JS
Int Immunol; 1994 May; 6(5):701-9. PubMed ID: 7521667
[TBL] [Abstract][Full Text] [Related]
38. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
Nijhuis EW; vd Wiel-van Kemenade E; Figdor CG; van Lier RA
Cancer Immunol Immunother; 1990; 32(4):245-50. PubMed ID: 2175673
[TBL] [Abstract][Full Text] [Related]
39. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
40. B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation.
Sansom DM; Wilson A; Boshell M; Lewis J; Hall ND
Immunology; 1993 Oct; 80(2):242-7. PubMed ID: 7505258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
